Pancreatic CancerNCT07612046
A Study of Magnetic Resonance Imaging of the Pancreas for Cancer Screening
An observational study of Pancreatic Cancer and Pancreas Cancer, run by Memorial Sloan Kettering Cancer Center at 7 sites in United States.
Trial summary
The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Cancer, Pancreas Cancer
- What is being tested?
- MRI and Endoscopic ultrasound
- How many people
- 79 participants
- Where
- 7 sitesUnited States
- Study dates
- 20 May 2026to 20 May 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Investigators will conduct this pilot study in high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry
Who may be able to join
- Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
- Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
- Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
- Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+
- For this pilot MRP study, we will additionally apply the following Criteria:
- Consents to follow-up contact
Show all 19Show fewer
- US residents
- Completed MRI with MRCP with no actionable findings related to the pancreas (e.g. a pancreatic mass)
- No metallic artifacts covering the pancreas on prior MRCP
- Scheduled for endoscopic ultrasound
- No new contraindications for MRI (e.g. new MR unsafe device)
- No history of claustrophobia or use of anxiolytic on prior MRI
- No history of abdominal surgery that may affect interpretation of either EUS or MR
- No medical conditions that confers increased and/or unacceptable risk for anesthesia
- We will recruit surveillance participants who had at least one prior MRCP in the last 3 years. They must also undergo a same-day EUS procedure as part of their surveillance. Nearly all active cohort participants have had at least one recent MRCP and, on average, our Registry gastroenterologist Dr. Rolston performs EUS in ~260 surveillance participants per year. Accordingly, it is highly feasible to recruit more than 79 participants in the grant period, and recruitment is constrained by budget.
- Documentation of Disease
- o No pathologic confirmation of disease is necessary
- Definition of Disease N/A
- Required Organ Function N/A
Who cannot join
- -
Trial locations and contacts
7 sites in 1 country. Contact the study team or a site near you to ask about taking part.
7 sites in 1 country
United States7 sites, 7 recruiting
- Recruiting
Memorial Sloan Kettering Basking Ridge (Consent Only)
Basking Ridge, New Jersey, 07920
Richard Kinh Gian Do, MD, PhD, 212-639-8591
- Recruiting
Memorial Sloan Kettering Suffolk-Commack (Consent only)
Commack, New York, 11725
Richard Kinh Gian Do, MD, PhD, 212-639-8591
- Recruiting
Memorial Sloan Kettering Westchester (Consent only)
Harrison, New York, 10604
Richard Kinh Gian Do, MD, PhD, 212-639-8591
- Recruiting
Memorial Sloan Kettering Monmouth (Consent only)
Middletown, New Jersey, 07748
Richard Kinh Gian Do, MD, PhD, 212-639-8591
- Recruiting
Memorial Sloan Kettering Bergen (Consent Only)
Montvale, New Jersey, 07645
Richard Kinh Gian Do, MD, PhD, 212-639-8591
- Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activites)
New York, New York, 10065
Richard Kinh Gian Do, MD, PhD, 212-639-8591
- Recruiting
Memorial Sloan Kettering Nassau (Consent Only)
Uniondale, New York, 11553
Richard Kinh Gian Do, MD, PhD, 212-639-8591
About this study
Official title: Pilot Study of a Dedicated MR of the Pancreas: Improving Screening for Patients at High Risk for Pancreas Cancer
The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.
- Conditions
- Pancreatic Cancer, Pancreas Cancer
- Being tested
- MRI, Endoscopic ultrasound
- Keywords
- Pancreatic Cancer, Pancreas Cancer, Memorial Sloan Kettering Cancer Center, 26-174
- Medical subject headings
- Pancreatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRIDiagnostic test
Also called Magnetic Resonance CholangioPancreatography, MRP
Participants will undergo a single MRI of the abdomen without contrast
Endoscopic ultrasoundDiagnostic test
Also called EUS
EUS will be scheduled the same day or within 2 weeks prior to MRP
| Study group | Role | What they receive |
|---|---|---|
| Participants at high risk for pancreas ductal adenocarcinoma | Participants will be high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry Receives: Diagnostic Test: MRI; Diagnostic Test: Endoscopic ultrasound |
What is being measured
The primary outcome is the main question the study is designed to answer.
Compare image quality of novel high-resolution magnetic resonance pancreas (MRP) to conventional MRCP
Develop and pilot a focused high-resolution magnetic resonance pancreas (MRP) exam to help facilitate early pancreatic cancer detection in high-risk individuals. Image quality for T1, T2, and DWI sequences performed on the novel MRP exam will be compared to conventional MRCP performed in the same participants.
Measured: Up to 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 May 2026
- Study start20 May 2026
- Primary completion20 May 2028 (estimated)
- Study completion20 May 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic CancerStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 79 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- Responsible party
- Sponsor
- Investigators
- Richard Kinh Gian Do, MD, PhD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07612046
- Sponsor's protocol ID
- 26-174
- Status last verified
- Jul 2026
- First submitted
- 21 May 2026
- Last updated
- 9 Jul 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: • Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Study at a glance
From the registry record, last updated by the sponsor on 9 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pilot Study of a Dedicated MR of the Pancreas: Improving Screening for Patients at High Risk for Pancreas Cancer
- ClinicalTrials.gov ID
- NCT07612046
- Acronym / sponsor ID
- 26-174
- Conditions
- Pancreatic Cancer, Pancreas Cancer
- Keywords
- Pancreatic Cancer, Pancreas Cancer, Memorial Sloan Kettering Cancer Center, 26-174
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 79 participants (estimated)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Collaborators
- National Institutes of Health (NIH)
- Study start
- 20 May 2026 (actual)
- Primary completion
- 20 May 2028 (estimated)
- Study completion
- 20 May 2028 (estimated)
- First posted
- 28 May 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to develop a dedicated MRI scan of the pancreas (MRP) to better detect pancreatic cancer in people who are at a high risk for pancreatic cancer.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Participants at high risk for pancreas ductal adenocarcinoma | – | Diagnostic Test: MRI, Diagnostic Test: Endoscopic ultrasoundParticipants will be high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Investigators will conduct this pilot study in high-risk individuals enrolled in the Memorial Sloan Kettering Pancreatic Tumor Registry
Key inclusion criteria (19 listed)
- Two first-degree relatives with pancreas cancer, one being a first-degree relative to the individual
- Pathogenic mutation in APC, BRCA1, MLH1, MSH2, MSH6, PMS2, EPCAM, PALB2, or TP53 and a first/second-degree relative with pancreas cancer
- Pathogenic mutation in CDKN2A/p16, STK11, PRSS1, SPINK1/PST1, CTRC, CPA1, ATM, or BRCA2
- Meets surveillance age eligibility, which is typically age 50, or 10 years earlier than the youngest relative with pancreas cancer. For individuals with certain gene mutations, this can be earlier. All participants must be aged 21+
- Consents to follow-up contact
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRIAlso: Magnetic Resonance CholangioPancreatography, MRPParticipants will undergo a single MRI of the abdomen without contrast | Diagnostic test | Participants at high risk for pancreas ductal adenocarcinoma |
| Endoscopic ultrasoundAlso: EUSEUS will be scheduled the same day or within 2 weeks prior to MRP | Diagnostic test | Participants at high risk for pancreas ductal adenocarcinoma |
Primary outcome
Compare image quality of novel high-resolution magnetic resonance pancreas (MRP) to conventional MRCP
Time frame: Up to 3 years
Develop and pilot a focused high-resolution magnetic resonance pancreas (MRP) exam to help facilitate early pancreatic cancer detection in high-risk individuals. Image quality for T1, T2, and DWI sequences performed on the novel MRP exam will be compared to conventional MRCP performed in the same participants.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Jul 2026.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
- Individual participant dataSharing planned: Yes. • Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.
Related trials for Pancreatic Cancer
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Richard Kinh Gian Do, MD, PhD principal investigator
Memorial Sloan Kettering Cancer Center
7 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Cancer and Pancreas Cancer, run by Memorial Sloan Kettering Cancer Center at 7 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 19 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 9 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 7 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Richard Kinh Gian Do, MD, PhD (212-639-8591, dok@mskcc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Compare image quality of novel high-resolution magnetic resonance pancreas (MRP) to conventional MRCP (time frame: Up to 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jul 2026.